Frontiers in oncology
Survey-based perspectives and reported barriers to DPYD testing among U.S. oncologists
By Tohme S, Salloum RG, De La Cruz J and 8 others.
Abstract
Background
Patients with cancer with deleterious DPYD variants are at significantly increased risk for severe toxicity with standard fluoropyrimidine doses. Prior to recent guidelines recommending it, the uptake of pre-treatment DPYD testing in the United States has been low. We aimed to explore oncologists' perceptions and barriers to DPYD testing adoption on a national level.
Materials and methods
Survey invitations were sent to U.S. oncologists listed in the American Medical Association (AMA) Masterfile in April and May 2025. The surveys assessed physician knowledge, attitudes, and perceptions of DPYD testing in clinics caring for patients with cancer in the United States. Descriptive statistics were used to evaluate survey responses.